Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL)

Renato Bassan, Orietta Spinelli, Elena Oldani, Tamara Intermesoli, Manuela Tosi, Barbara Peruta, Giuseppe Rossi, Erika Borlenghi, Enrico M. Pogliani, Elisabetta Terruzzi, Pietro Fabris, Vincenzo Cassibba, Giorgio Lambertenghi-Deliliers, Agostino Cortelezzi, Alberto Bosi, Giacomo Gianfaldoni, Fabio Ciceri, Massimo Bernardi, Andrea Gallamini, Daniele MatteiEros Di Bona, Claudio Romani, Anna Maria Scattolin, Tiziano Barbui, Alessandro Rambaldi

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL)'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemical Compounds